111 Debt to Equity Ratio 2018-2025 | YI
Current and historical debt to equity ratio values for 111 (YI) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. 111 debt/equity for the three months ending March 31, 2025 was 0.00.
| 111 Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2025-03-31 | $0.45B | $-0.09B | -4.87 |
| 2024-12-31 | $0.47B | $-0.09B | -5.24 |
| 2024-09-30 | $0.52B | $-0.09B | -5.76 |
| 2024-06-30 | $0.47B | $-0.09B | -5.48 |
| 2024-03-31 | $0.49B | $-0.08B | -5.86 |
| 2023-12-31 | $0.52B | $-0.08B | -6.19 |
| 2023-09-30 | $0.53B | $-0.07B | -7.52 |
| 2023-06-30 | $0.48B | $-0.06B | -7.87 |
| 2023-03-31 | $0.53B | $-0.06B | -8.73 |
| 2022-12-31 | $0.56B | $-0.06B | -9.50 |
| 2022-09-30 | $0.48B | $-0.05B | -9.47 |
| 2022-06-30 | $0.51B | $-0.05B | -11.27 |
| 2022-03-31 | $0.51B | $-0.04B | -13.66 |
| 2021-12-31 | $0.52B | $-0.02B | -21.68 |
| 2021-09-30 | $0.50B | $-0.01B | -57.57 |
| 2021-06-30 | $0.49B | $0.03B | 19.11 |
| 2021-03-31 | $0.43B | $0.05B | 9.52 |
| 2020-12-31 | $0.40B | $0.06B | 6.45 |
| 2020-09-30 | $0.33B | $0.07B | 4.69 |
| 2020-06-30 | $0.18B | $0.08B | 2.19 |
| 2020-03-31 | $0.14B | $0.10B | 1.46 |
| 2019-12-31 | $0.12B | $0.11B | 1.08 |
| 2019-09-30 | $0.10B | $0.13B | 0.78 |
| 2019-06-30 | $0.10B | $0.15B | 0.68 |
| 2019-03-31 | $0.08B | $0.16B | 0.46 |
| 2018-09-30 | $0.05B | $0.19B | 0.27 |
| 2018-06-30 | $0.32B | $-0.16B | -2.02 |
| 2017-12-31 | $0.26B | $-0.14B | -1.81 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.060B | $1.973B |
| 111, Inc. operates as a digital and mobile healthcare platform. The Company offers pharmacy distribution, medical consultancy, e-prescription and other services. 111, Inc. is headquartered in Shanghai, China. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Veeva Systems (VEEV) | United States | $46.937B | 59.72 |
| Hims & Hers Health (HIMS) | United States | $13.490B | 140.16 |
| Doximity (DOCS) | United States | $11.213B | 51.91 |
| Tempus AI (TEM) | United States | $10.091B | 0.00 |
| IRhythm Technologies (IRTC) | United States | $4.366B | 0.00 |
| Inspire Medical Systems (INSP) | United States | $3.822B | 59.72 |
| Hinge Health (HNGE) | United States | $3.402B | 0.00 |
| Privia Health (PRVA) | United States | $2.375B | 162.33 |
| 10x Genomics (TXG) | United States | $1.724B | 0.00 |
| Phreesia (PHR) | United States | $1.614B | 0.00 |
| Enovis (ENOV) | United States | $1.561B | 8.70 |
| Schrodinger (SDGR) | United States | $1.553B | 0.00 |
| Azenta (AZTA) | United States | $1.553B | 72.17 |
| Clover Health Investments (CLOV) | United States | $1.471B | 0.00 |
| Omnicell (OMCL) | United States | $1.387B | 24.48 |
| Evolent Health (EVH) | United States | $1.105B | 94.10 |
| Claritev (CTEV) | United States | $0.635B | 0.00 |
| Fulgent Genetics (FLGT) | United States | $0.535B | 0.00 |
| Standard BioTools (LAB) | United States | $0.528B | 0.00 |
| Veradigm (MDRX) | United States | $0.503B | 0.00 |
| Butterfly Network (BFLY) | United States | $0.453B | 0.00 |
| Talkspace (TALK) | United States | $0.420B | 125.50 |
| TruBridge (TBRG) | United States | $0.328B | 728.00 |
| Outset Medical (OM) | United States | $0.311B | 0.00 |
| Health Catalyst (HCAT) | United States | $0.273B | 0.00 |
| Nyxoah SA (NYXH) | Belgium | $0.255B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.218B | 0.00 |
| CapsoVision (CV) | United States | $0.210B | 0.00 |
| Zepp Health (ZEPP) | Netherlands | $0.182B | 0.00 |
| KORU Medical Systems (KRMD) | United States | $0.161B | 0.00 |
| American Well (AMWL) | United States | $0.129B | 0.00 |
| Pulmonx (LUNG) | United States | $0.124B | 0.00 |
| EUDA Health Holdings (EUDA) | Singapore | $0.122B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.117B | 0.00 |
| CareCloud (CCLD) | United States | $0.100B | 3.82 |
| ImmunoPrecise Antibodies (IPA) | Canada | $0.079B | 0.00 |
| Insight Molecular Diagnostics (IMDX) | United States | $0.078B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.042B | 0.00 |
| HeartBeam (BEAT) | United States | $0.041B | 0.00 |
| Zhongchao (ZCMD) | China | $0.025B | 0.00 |
| Streamline Health Solutions (STRM) | United States | $0.023B | 0.00 |
| Precipio (PRPO) | United States | $0.022B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.021B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.014B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.008B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.008B | 0.00 |
| MSP Recovery (MSPR) | United States | $0.008B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.006B | 0.00 |
| Movano (MOVE) | United States | $0.005B | 0.00 |
| PROFUSA (PFSA) | United States | $0.005B | 0.00 |
| Evaxion - (EVAX) | Denmark | $0.004B | 0.00 |
| HeartSciences (HSCS) | United States | $0.004B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.004B | 0.00 |
| Future Health ESG (FHLT) | United States | $0.000B | 0.00 |